Continuous release of interleukin 12 from microencapsulated engineered cells for colon cancer therapy

Figure 1 NIH3T3-mIL-12 cells-loaded microcapsules (average capsule diameter 450 µm).

Figure 2 NK activity induced by various treatment. ^-x±s, n = 10, ^bP < 0.01 for the group treated with NIH3T3-mIL-12 cells capsule versus other three counterpart groups, respectively.

Figure 3 CTL activity against CT26 induced by various treatment. ^-x±s, n = 10, ^bP < 0.01 for the group treated with NIH3T3-mIL-12 cells capsule versus other three counterpart groups, respectively.

Figure 4 Cytokines levels in serum after various treatment in the tumor-bearing model. ^-x±s, n = 10, ^bP < 0.01 for the group treated with NIH3T3-mIL-12 cells capsule versus other three counterpart groups, respectively.

Figure 5 Inhibition of tumor growth by microencapsulated NIH3T3-mIL-12. Two days after tumor inoculation, mice were injected sc with NIH3T3-mIL-12 cells capsule (▲), NIH3T3-mIL-12 cells (△), NIH3T3 cells capsule (●) or RPMI-1640 (○). ^-x±s, n = 20, ^aP < 0.05 for the group treated with NIH3T3-mIL-12 cells capsule versus other three counterpart groups respectively.

Figure 6 Survival time after various treatment in the tumor-bearing model. Two days after tumor inoculation, mice were injected sc with RPMI-1640 (○), NIH3T3 cells capsule (●), NIH3T3-mIL-12 cells (△) and NIH3T3-mIL-12 cells capsule (▲), respectively. Ten tumor-bearing mice (n = 10) in each group were observed for their survival time. All surviving mice were monitored for at least 60 d. ^aP < 0.05, compared with other three counterpart groups, respectively.